SCHEDULE: Millennium Management Discloses 2.8% Stake in Reviva Pharma

Millennium Management and affiliated entities report a 2.8% beneficial ownership stake in Reviva Pharmaceuticals Holdings, Inc. as of December 31, 2025.

Summary

• Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander collectively reported beneficial ownership of common stock in Reviva Pharmaceuticals Holdings, Inc.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating an update to previously reported beneficial ownership.
• As of December 31, 2025, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each beneficially owned 3,257,670 shares, representing 2.8% of the class.
• Integrated Core Strategies (US) LLC beneficially owned 3,254,631 shares, also representing 2.8% of the class.
• All reporting persons have shared voting and shared dispositive power over the reported shares.
• The reporting persons certified that the securities were not acquired for the purpose of changing or influencing control of Reviva Pharmaceuticals Holdings, Inc.

Sentiment

Score: 6

Explanation: The filing indicates a significant institutional investor, Millennium Management, holds a 2.8% stake, which is a neutral to slightly positive signal of institutional interest, though not a controlling position.

Positives

• The disclosure of a 2.8% stake by a prominent investment firm like Millennium Management indicates institutional interest in Reviva Pharmaceuticals Holdings, Inc.

Future Outlook

NA

Management Comments

• The reporting persons certify that, to the best of their knowledge and belief, the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This Schedule 13G filing indicates that Millennium Management, a significant hedge fund, holds a notable, albeit non-controlling, stake in Reviva Pharmaceuticals. Such disclosures are routine for institutional investors and provide transparency into significant ownership positions in publicly traded companies, often signaling institutional confidence or strategic positioning within a sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and trading activity.

Key Dates

Keywords

Reviva Pharmaceuticals Holdings Inc, Millennium Management, Schedule 13G, Beneficial Ownership, Institutional Investment, Common Stock, SEC Filing